Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer's disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington's disease based on similarities to neuroimmune pathology in Alzheimer's ROCHESTER, N.Y., July 31, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (NASDAQ:VCNX), a clinical-stage biotechnology company pioneering treatment of Alzheimer's disease (AD) with anti-Semaphorin 4D (SEMA4D) antibody, ...